Related by context. All words. (Click for frequent words.) 87 CYPHER R Stent 76 CYPHER Stent 75 TAXUS stent 74 Taxus Stent 72 TAXUS 72 TAXUS Stent 70 XIENCE V stent 70 TAXUS Liberte Stent 69 CYPHER R Sirolimus eluting 69 Endeavor stent 68 TAXUS Express Stent 68 carotid stenting 68 paclitaxel eluting stent 68 NEVO ™ 68 paclitaxel eluting stents 67 mm Stent 67 sirolimus eluting stent 67 XIENCE V PROMUS Stent 66 definite stent thrombosis 66 everolimus eluting stent 66 Cypher Stent 66 XIENCE V 66 MACCE 66 TAXUS Liberte stent 66 HORIZONS AMI trial 65 CYPHER ® Sirolimus eluting 65 TAXUS Express 65 target lesion revascularization 65 sirolimus eluting stents 65 XIENCE V Everolimus Eluting 65 GORE VIABAHN Endoprosthesis 65 Resolute DES 65 ischemic cardiomyopathy 65 TAXUS Liberte Long 64 carotid endarterectomy CEA 64 binary restenosis 64 XIENCE V demonstrated 64 TAXUS ® 64 TAXUS Liberte 64 coronary interventions 64 TAXUS VI 64 ATACAND 64 carotid artery stenting 64 Endeavor drug eluting 64 Stent System 64 ARIXTRA 64 active comparator 64 bivalirudin 64 SPIRIT IV 64 RE LY ® 64 CYPHER ® 64 carotid artery stenting CAS 64 everolimus eluting stents 64 Coronary Stent 64 XGEVA 64 ENDEAVOR clinical 64 acute coronary syndromes ACS 64 TAXUS stents 64 KRAS mutations occur 63 ARCOXIA 63 composite endpoint 63 pegylated interferon alfa 2b 63 PRECiSE 63 placebo controlled clinical 63 eplerenone 63 ACTEMRA 63 dabigatran etexilate 63 FOLFOX4 63 FFR guided treatment 63 Sirolimus eluting Coronary Stent 63 SPIRIT III 63 coronary intervention 63 Endeavor DES 63 chlorambucil 63 STEMI patients 63 enoxaparin 63 plus dexamethasone 62 telmisartan 62 drug eluting stent 62 zotarolimus eluting stent 62 MitraClip device 62 paclitaxel eluting 62 TAXUS TM 62 rivaroxaban 62 patients undergoing percutaneous 62 TAXUS Element Stent 62 TAXUS IV 62 CIMZIA ™ 62 nonrandomized 62 TAXUS V 62 fondaparinux 62 RE LY 62 TAXUS R 62 drug eluting stent DES 62 NATRECOR ® 62 TRITON TIMI 62 adalimumab 62 rosuvastatin 62 NEVO 62 oral diclofenac 62 SYNTAX trial 62 tiotropium 62 placebo dexamethasone 62 prospective multicenter 62 ACTEMRA TM 62 repeat revascularization 62 SYNTAX 62 valsartan 62 TORISEL 62 SPIRIT FIRST 61 MitraClip 61 sirolimus eluting 61 COPAXONE R 61 ABSORB 61 events MACE 61 drug eluting stents 61 transfemoral 61 endarterectomy 61 candesartan 61 Doxil ® 61 ACUITY trial 61 stent DES 61 evaluating REVLIMID 61 carboplatin paclitaxel 61 tolvaptan 61 ADHF 61 unstable angina UA 61 Events MACE 61 ticagrelor 61 sunitinib malate 61 MADIT CRT 61 Atom Stent 61 PROMUS Element Stent 61 nesiritide 61 NSTE ACS 61 dual antiplatelet therapy 61 MACUGEN 61 noninferiority 61 Angiox R 61 prospective randomized controlled 61 ximelagatran 61 tirofiban 61 Protelos 61 carotid endarterectomy 61 rFVIIa 61 FOLPI 61 reinfarction 61 thrombolytic agents 61 DEFINITY ® 61 relapsed SCLC 61 #mg BID [001] 61 multivessel disease 61 angiographic outcomes 61 aldosterone antagonist 61 CIMZIA TM 61 PROMUS 61 Resolute drug eluting 61 thromboprophylaxis 60 rosuvastatin #mg 60 TAVR 60 irbesartan 60 mycophenolate mofetil 60 Nitinol Stent 60 CANCIDAS 60 morphometric vertebral fractures 60 symptomatic VTE 60 clopidogrel Plavix 60 decitabine 60 Edwards SAPIEN valve 60 randomized controlled clinical 60 reintervention 60 stable angina 60 percutaneous intervention 60 Thrombolysis 60 tapentadol ER 60 Coronary Stent System 60 angiotensin receptor blocker ARB 60 Heparin Bioactive Surface 60 atherothrombotic disease 60 randomized Phase III 60 unfractionated heparin 60 perioperative mortality 60 thromboembolic events 60 EVEREST II 60 revascularization procedures 60 EURIDIS 60 ONTARGET 60 GP IIb IIIa inhibitors 60 NATRECOR R 60 stent thrombosis 60 non valvular atrial 60 stent thromboses 60 patients undergoing CABG 60 DAPT 60 standard chemotherapy regimen 60 coronary stenting 60 oral allopurinol 60 ST elevation myocardial 60 sirolimus stent 60 interferon beta therapy 60 levosimendan 60 nondiabetic patients 60 diameter stenosis 60 ACCORD Lipid 60 acute myocardial infarction AMI 60 carotid artery stent 60 stenting 60 Combo Stent 60 OPCAB 60 revascularization 60 CYPHER R 59 fluvastatin 59 Zilver PTX 59 oral FTY# 59 Cotavance 59 vertebral fractures 59 Genous stent 59 CYPHER R stent 59 Dr. Kandzari 59 Betaferon ® 59 Endarterectomy 59 ONGLYZA 59 neoadjuvant 59 systemic embolism 59 plus prednisone 59 XELOX 59 Operative mortality 59 MADIT CRT trial 59 SUPERA stent 59 acute coronary syndrome 59 EchoCRT 59 SEROQUEL 59 octreotide LAR 59 NEVO TM 59 YERVOY 59 oncologic outcomes 59 endovascular repair 59 Tryton Side Branch 59 preoperative chemotherapy 59 antiplatelet therapy 59 multicenter clinical 59 PTNS 59 BRIM2 59 antiplatelet agents 59 percutaneous coronary interventions 59 dosage regimens 59 chemotherapy gemcitabine 59 vandetanib 59 antithrombotic therapy 59 TAXUS Liberté 59 randomized controlled clinical trials 59 pain palliation 59 thrombus aspiration 59 azacitidine 59 VELCADE melphalan 59 carotid surgery 59 EDEMA3 59 HUMIRA 59 pegylated liposomal doxorubicin 59 HoLEP 59 tipranavir 59 oxycodone CR 59 lopinavir r arm 59 ruboxistaurin 59 certolizumab 59 cinacalcet 59 STELARA 59 PFO closure 59 Atacand 59 Kaplan Meier analysis 59 ToGA 59 imipenem 59 mcg albinterferon alfa 2b 59 Fludara 59 ULORIC 59 alteplase 59 oral anticoagulation 59 severe aortic stenosis 59 anti arrhythmic drug 59 mg QD 59 radical nephrectomy 59 coronary revascularization 59 melphalan prednisone 59 placebo controlled Phase III 58 chemoradiotherapy 58 Stent thrombosis 58 PROMUS ® 58 noninferior 58 posaconazole 58 thrombotic events 58 INCB# [003] 58 MabCampath 58 de novo lesions 58 balloon kyphoplasty 58 stent implantation 58 stent grafts 58 bosentan 58 myocardial infarction MI 58 Endeavor Resolute 58 GP IIb IIIa inhibitor 58 teriflunomide 58 TAXUS ATLAS 58 INTEGRILIN 58 SCD HeFT 58 primary patency 58 HuMax EGFr 58 OZURDEX ® 58 thrombolytic therapy 58 pioglitazone 58 clopidogrel 58 APPRAISE 58 Major Adverse Cardiac 58 Torisel 58 RESOLUTE clinical 58 ABSORB trial 58 TAVI 58 GORE TAG Device 58 SUTENT 58 pCR 58 TAXUS p value 58 acute coronary syndromes 58 gadobutrol 58 stent restenosis 58 eptifibatide 58 peginterferon alfa 2a 58 renal tumors 58 ARB telmisartan 58 myocardial infarction stroke 58 mg BID dose 58 IFN alfa 58 ZoMaxx 58 tocilizumab 58 ipsilateral stroke 58 transcatheter aortic valve implantation 58 analgesic efficacy 58 cardiovascular hospitalization 58 Amrubicin 58 comparator arm 58 XIENCE PRIME 58 PROMUS Element Everolimus Eluting 58 sunitinib 58 tipranavir r 58 V Everolimus Eluting Coronary 58 subgroup analyzes 58 ARIMIDEX 58 NeuroStar TMS Therapy 58 metastatic CRC 58 free survival PFS 58 Eluting Coronary Stent System 58 VADT 58 multicentre randomized 58 oral Xeloda 58 adult chronic ITP 58 EverFlex 58 cilostazol 58 doxorubicin docetaxel 58 Cordis Cypher 58 paclitaxel eluting coronary stent 58 COPAXONE ® 58 DES implantation 58 RAPAFLO R 58 ENDEAVOR IV 58 TAXUS Liberté stent 58 CABG surgeries 58 Stenting Trial CREST 58 Tavocept 58 DOXIL 58 Engerix B 58 plus gemcitabine 58 methotrexate monotherapy 58 functional mitral regurgitation 58 Xience V 58 CCyR 58 SYNERGY Stent 58 TACE 58 CIMZIA TM certolizumab pegol 58 rosuvastatin Crestor 58 relapsed refractory multiple myeloma 58 ALLHAT 58 primary percutaneous coronary 58 infarction STEMI 58 ExTRACT TIMI 58 clopidogrel Plavix ® 58 Multaq R 58 Hazard Ratio 58 afatinib 58 VIDAZA 58 recurrent GBM 58 idraparinux 58 vertebral compression fractures 58 FOLFOX 58 SYMBICORT 58 PERSEUS 58 Pemetrexed 58 vinorelbine 58 RoACTEMRA 58 stent BMS 58 temsirolimus 58 TNF antagonists 58 carotid stent 58 dacarbazine 58 CYPHER 58 NEXIUM 57 prospective randomized 57 bronchial thermoplasty 57 TEVAR 57 coronary lesions 57 neoadjuvant treatment 57 non squamous NSCLC 57 sirolimus 57 aldosterone antagonists 57 abatacept 57 Halaven 57 tolerability 57 LVEF 57 non inferiority 57 WBRT 57 paroxysmal AF 57 Aromasin 57 sorafenib Nexavar 57 GAMMAGARD 57 unstable angina pectoris 57 baseline HbA1c 57 Carotid Revascularization Endarterectomy vs. 57 ENDEAVOR II 57 bifurcation lesions 57 eculizumab 57 trabectedin 57 XIENCE TM 57 PROMACTA 57 transapical 57 candesartan cilexetil 57 ACR# response 57 ION Stent 57 Everolimus Eluting Coronary Stent 57 LMWH 57 multicenter randomized 57 Median survival 57 β blockers 57 TAXUS Express2 57 fluticasone salmeterol 57 nonfatal MI 57 cisplatin vinorelbine 57 cytoreductive surgery 57 defibrillator CRT D 57 angiotensin II receptor blocker 57 aspirin clopidogrel 57 mg kg dose 57 phase IIIb 57 efficacy endpoint 57 LEXIVA r 57 iodixanol 57 mcg QD 57 drug eluting coronary stents 57 target vessel revascularization 57 chronic angina 57 randomized clinical 57 thoracoscopic lobectomy 57 pertuzumab 57 Myocardial Infarction Study 57 thrombolysis 57 elective PCI 57 certolizumab pegol 57 metastatic HRPC 57 Target Lesion Revascularization TLR 57 ™ Everolimus Eluting 57 dalteparin 57 strontium ranelate 57 lipid lowering therapy 57 XIENCE V vs. 57 dyslipidaemia 57 carotid stents 57 cardiovascular hospitalizations 57 relapsing multiple sclerosis 57 Dabigatran 57 tolerability profile 57 Multicenter Automatic Defibrillator Implantation 57 ASTEROID 57 fenofibric acid 57 Telmisartan 57 Traficet EN 57 postoperative chemotherapy 57 vertebral fracture 57 Vascugel ® 57 Raptiva r 57 ularitide 57 docetaxel chemotherapy 57 Perforomist Inhalation Solution 57 cardiac toxicity 57 thromboembolic 57 AVANDIA 57 reperfusion therapy 57 plus methotrexate 57 PROMUS Element 57 PROactive study 57 beta blocker therapy 57 HBeAg negative patients 57 lumbar spine BMD 57 RX ACCULINK 57 FOLFIRI 57 MADIT II 57 oral anticoagulant 57 Ceplene/IL-2 57 myocardial infarctions 57 tenecteplase 57 axitinib 57 gemcitabine carboplatin 57 MitraClip R 57 workhorse lesions 57 HBeAg positive patients 57 lymphadenectomy 57 anastrozole 57 degarelix 57 VTE prophylaxis 57 pegylated interferon alfa 57 liver transplant recipients 57 ICD implantation 57 statin therapy 56 recurrent VTE 56 aspirin beta blockers 56 unfractionated heparin UFH 56 ZYVOX 56 colorectal liver metastases 56 biologic DMARD 56 Mylotarg 56 revascularization procedure 56 palonosetron 56 etanercept 56 metastatic RCC 56 hemodialysis patients 56 nab paclitaxel 56 mcg dose 56 concurrent chemoradiation 56 Arixtra 56 dronedarone 56 Express2 TM Paclitaxel Eluting 56 APTIVUS r 56 tanespimycin 56 deferiprone 56 rt PA 56 COMFORT II 56 solid organ transplantation 56 virologic response 56 glimepiride 56 peginterferon alfa 2a #KD 56 5-FU/LV 56 BENICAR HCT 56 neoadjuvant therapy 56 VIDAZA azacitidine 56 Secondary endpoints 56 relapsed MM 56 PASI scores 56 dose dexamethasone 56 TAXUS Element Paclitaxel Eluting 56 pomalidomide 56 Clinical Outcomes Utilizing Revascularization 56 crizotinib PF # 56 FOLFOX regimen 56 achieved ACR# 56 hsCRP levels 56 ROCKET AF 56 eribulin 56 thromboembolism 56 apixaban 56 Vectibix monotherapy 56 olaparib 56 DU #b 56 FIRMAGON 56 antithrombotics 56 randomized clinical trials 56 zotarolimus 56 antiplatelet drugs 56 nephron sparing surgery 56 antihypertensive therapy 56 label multicenter 56 PRADAXA 56 secondary efficacy endpoint 56 amoxicillin clavulanate 56 chemoradiation therapy 56 intracranial stenosis 56 acute ischemic stroke 56 saphenous vein grafts 56 death reinfarction 56 insulin glargine 56 CRESTOR #mg 56 Rivaroxaban 56 custirsen 56 fully bioabsorbable 56 sipuleucel T 56 ezetimibe simvastatin 56 FluCAM 56 preventing restenosis 56 NOXAFIL 56 TAXUS Express Atom Stent 56 lacosamide 56 infusional 5-FU/LV 56 INC# 56 carotid IMT 56 TEMODAL 56 Visipaque 56 prospective multicenter randomized 56 peginterferon alfa 2b 56 daunorubicin 56 pimecrolimus 56 BRAF inhibitor 56 teriparatide 56 IV NSCLC 56 oral rivaroxaban 56 Taxotere ® 56 microvascular complications 56 virologic failure 56 periprocedural 56 platelet inhibitor 56 undergoing coronary artery 56 mcg Albuferon 56 NYHA functional class 56 microbiological eradication 56 symptomatic carotid stenosis 56 ReoPro 56 acute PAO 56 endovascular therapy 56 iniparib 56 nonoperative 56 antiarrhythmic drug 56 recurrent NSCLC 56 lopinavir r 56 nonobstructive CAD 56 median PFS 56 esomeprazole 56 ADAGIO study 56 postoperative mortality 56 Octreolin 56 Lantus ® 56 revascularisation 56 pitavastatin 56 secondary endpoint 56 locoregional recurrence 56 docetaxel Taxotere ® 56 LEUKINE 56 pazopanib 56 angiographic restenosis 56 SLNB 56 pneumonectomy 56 briakinumab 56 nonvertebral fracture 56 sustained virological response 56 subtrochanteric 56 WallFlex Biliary RX 56 GOUT 56 arterial thromboembolic events 56 Vascular Wrap 56 Atacand ® 56 chemoradiation 56 lipid lowering agents 56 CUSTOM III 56 ramipril 56 #mg dose [001] 56 discontinuations due 56 chemoembolization 56 bypass graft CABG surgery 56 eluting stents 56 everolimus 56 ABVD 56 gemcitabine Gemzar 56 lipid lowering drugs 56 radiochemotherapy 56 Rebif ® 56 liposomal doxorubicin 56 ReValving 56 complete cytogenetic response 56 intravenous bisphosphonates 56 carotid artery stenosis 56 evaluating tivozanib 56 debulking surgery 56 FOSRENOL R 56 pharmacokinetic characteristics 56 efficacy tolerability 56 phase IIb clinical 56 Express2 TM paclitaxel eluting 56 QuadraSphere 56 zalutumumab 56 ACE inhibitor ramipril 56 peripheral stent 56 zoledronic acid 56 abciximab 56 Jevtana 56 TTF Therapy 56 Free Survival PFS 56 titrated glipizide 56 ePTFE graft 56 PROMUS TM 56 ICD therapy 56 biologic therapy 56 clodronate 55 XIENCE 55 delafloxacin 55 stage IIIb IV 55 AIM HIGH 55 receiving golimumab 55 MiniArc 55 STRIDE PD 55 ZOLINZA 55 #mg QD [002] 55 dose clopidogrel 55 neurologic progression 55 eluting stent 55 hepatectomy 55 MTWA testing 55 Spiriva Handihaler 55 adjuvant radiation 55 BR.# study 55 doripenem 55 acute STEMI 55 Imprime PGG 55 UA NSTEMI 55 PSADT 55 low dose Iluvien 55 LAGB 55 NSABP C 55 cerebrovascular events 55 epoetin alfa 55 apremilast 55 glycoprotein IIb IIIa inhibitors 55 CR nPR 55 NYHA Class II 55 simvastatin ezetimibe 55 Diovan HCT 55 multicenter prospective 55 bevacizumab 55 bendamustine 55 metastatic GIST 55 stented 55 olmesartan 55 ACRIN 55 tamoxifen Nolvadex ® 55 PressureWire 55 HSCT 55 ketorolac 55 STEMI ST 55 infarct size 55 sustained virologic response 55 serologically active patients 55 platinum chromium alloy 55 MoxDuo TM IR 55 conventional angiography 55 IIIa inhibitor 55 riociguat 55 invasive candidiasis 55 ALND 55 clinically meaningful efficacy 55 Acute Coronary Syndromes ACS 55 ® Everolimus Eluting 55 secondary efficacy endpoints 55 risedronate 55 #mg doses [002] 55 GEM OS1 55 Keppra R 55 Long Lesion 55 Endoprosthesis 55 atherothrombotic events 55 colesevelam HCl 55 graft patency 55 prostate TURP 55 Taxotere R 55 Acute Myocardial Infarction 55 EBRT 55 ablation procedures 55 liver resection 55 lumiracoxib 55 mg BID 55 ivabradine 55 myocardial reperfusion 55 preintervention 55 Bivalirudin 55 cardiovascular morbidity 55 DMARD 55 thrombolytics 55 PROMUS Stent 55 romiplostim 55 REMINYL ® 55 PROCHYMAL 55 CARE HF 55 pioglitazone Actos 55 Drug eluting stent 55 pamidronate 55 oral deforolimus 55 VFEND 55 recurrent glioblastoma multiforme 55 APTIVUS 55 placebo controlled Phase 55 STEMI 55 CYCLOSET 55 venous thromboembolism 55 relapsed multiple myeloma 55 PCIs 55 Pegasys ® 55 REMICADE ® 55 PREZISTA r 55 DAS# remission 55 AVONEX 55 Instanyl 55 drug zotarolimus 55 Acute Ischemic Stroke 55 Candesartan 55 osteoporotic compression fractures 55 tamsulosin 55 Perforomist ™ Inhalation Solution 55 DASISION 55 percutaneous transluminal coronary angioplasty 55 dose cytarabine 55 oral ridaforolimus 55 TYKERB 55 Azedra 55 YONDELIS 55 placebo controlled trials 55 Fractional Flow Reserve 55 FAMPYRA 55 NEVO RES 55 Xelox 55 interferon gamma 1b 55 antiplatelet agent 55 nonfatal myocardial infarction 55 Welchol 55 PEG INTRON 55 fundoplication 55 ALGRX 55 locoregional disease 55 postmenopausal osteoporotic women 55 multicentre 55 EVIZON 55 splenectomized patients 55 OZURDEX 55 Val HeFT 55 endophthalmitis 55 salmeterol fluticasone 55 calcineurin inhibitors 55 pharmacodynamic profile 55 AIR CF2 55 low dose cytarabine 55 AneuRx 55 dose regimens 55 forodesine 55 IRESSA 55 lupus nephritis 55 DexaSite 55 mg/m2 dose 55 pioglitazone HCl 55 fibrinolytic therapy 55 Novartis Zometa 55 stenoses 55 BAY #-# 55 infrapopliteal 55 atrasentan 55 BROVANA 55 trials RCTs 55 achieved statistical significance 55 topotecan 55 CHARISMA trial 55 JANUVIA 55 GFT# 55 replacement TAVR 55 ACR# responses 55 complete remissions 55 phase IIa clinical 55 bivalirudin monotherapy 55 BCIRG 55 bicalutamide 55 regorafenib 55 alvimopan 55 nonfasting triglyceride levels 55 fenofibrate 55 postintervention 55 mg dose 55 HeFT 55 stenting procedures 55 mRCC 55 dosing regimens 55 FROVA 55 HORIZONS AMI 55 NYHA Class III 55 Thal Dex 55 cryptogenic stroke 55 Catena ® 55 FFR measurements 55 TAXUS Element Stent System 55 losartan 55 NSAID 55 thromboembolic complications 55 VICTRELIS 55 INT# [002] 55 ponatinib 55 docetaxel Taxotere R 55 segment elevation myocardial 55 angioplasty stenting 55 Baseline characteristics 55 Angiox 55 symptomatic aortic stenosis 55 multicenter trials 55 dacarbazine chemotherapy 55 Ophena TM 55 SORT OUT III 55 amlodipine 55 LUX Lung 55 extracranial 55 Lupuzor ™ 55 SCIg 55 hemoglobin A1c levels 55 NP2 Enkephalin 55 biochemical recurrence 55 muraglitazar 55 squamous histology 55 cardiac resynchronization 55 Xience 55 Rasilez Tekturna 55 subanalysis 55 adjuvant radiotherapy 55 pemetrexed 55 BENICAR 55 Medtronic Endeavor 55 Bare Metal Stent 55 ACE inhibitor 55 oxaliplatin Eloxatin 55 MIRCERA 55 FluCAM arm 55 carotid stenting procedures 55 Stenting 55 peginterferon alfa 2a Pegasys 55 parathyroidectomy 55 BeneFIX 55 elotuzumab 55 TAXUS paclitaxel eluting stent 55 INEGY 55 CALGB # [002] 55 fluorouracil 55 cardiac resynchronization therapy 55 atherothrombosis 55 chronic periodontitis 54 plus MTX 54 conventional coronary angiography 54 intravenous diuretics 54 PLCO 54 ACEI ARB 54 bisphosphonate therapy 54 Cimzia TM 54 segment binary restenosis 54 Delcath PHP System 54 refractory angina 54 asymptomatic carotid stenosis 54 percutaneous vertebroplasty 54 adjuvant tamoxifen 54 neoadjuvant chemotherapy 54 REVLIMID 54 prasugrel Effient 54 Epoetin alfa 54 tigecycline 54 GIK infusion 54 catheter occlusion 54 elagolix 54 brivaracetam 54 insulin detemir 54 transcatheter aortic valve 54 aortic insufficiency 54 rimonabant #mg 54 drotrecogin alfa activated 54 coronary stent implantation 54 demonstrated clinically meaningful 54 desvenlafaxine succinate 54 recurrent ischemia 54 aspirin heparin 54 Targretin 54 CABG surgery 54 LPV r 54 HydroCoil 54 uterine fibroid embolization 54 EOquin TM 54 partial nephrectomy 54 non selective NSAIDs 54 bioabsorbable stent 54 pegfilgrastim 54 infarction NSTEMI 54 endoscopic remission 54 taxane therapy 54 events AEs 54 HBeAg seroconversion 54 AEGR 54 Certican 54 PARTNER Trial 54 ProSavin 54 Elitek 54 μg dose 54 heavily pretreated 54 gemcitabine chemotherapy 54 left ventricular dysfunction 54 Zilver PTX stent 54 SVR# 54 cediranib 54 RAPAFLO 54 Natalizumab 54 MERLIN TIMI